How to Read a Stool Test: A Practitioner's Guide to GI-MAP, Gut Zoomer, and Real Root-Cause Protocols
You already know the gut is the issue. You've told the client that. What you might not have is a clear answer for what to do next.
That's not a knowledge gap — it's a training gap. Most coaches and practitioners were never actually taught how to read a comprehensive stool test. So a panel comes back, the report is a wall of markers and reference ranges, and the result is either a generic gut protocol thrown at every client or an expensive test that never really gets used.
This guide walks through how stool testing actually works, what a report can and can't tell you, how GI-MAP, Gut Zoomer, and GI Effects compare, why SIBO needs a completely different test, what the individual markers on a report actually mean, and — the part most guides skip — how to turn a set of results into an actual sequenced protocol instead of a list of supplements matched to flagged values.
Table of Contents
How to Read a Stool Test: A Practitioner's Guide to GI-MAP, Gut Zoomer, and Real Root-Cause Protocols
Why "Reading the Lab" Is the Missing Skill
Picture a client with bloating, irregularity, food sensitivities, fatigue, skin flares, or brain fog. You already know the gut is involved — so you run a stool test expecting clarity.
What comes back instead is a wall of markers, color-coded high/low flags, and reference ranges that look different depending on which lab ran it. There's no obvious line from "here's the data" to "here's the protocol." So the default becomes one of two things: the same general gut protocol for every client, or chasing every red flag on the report at once.
Neither works. The real issue isn't a lack of intelligence or effort — it's that interpreting a comprehensive stool panel is a specific, learnable skill that almost nobody in this field was formally taught. Once you can read the report as a map instead of a wall of noise, you know what to address first, what to leave alone, and why.
What a Stool Test Can — and Can't — Tell You
What it can tell you
Digestive and absorptive capacity — pancreatic enzyme output, fat digestion, fiber breakdown
Inflammation in the GI tract — and whether it warrants a referral
The microbial terrain — commensal diversity, opportunistic overgrowth, fungi, parasites, pathogens
Gut immune and barrier function — secretory IgA, intestinal permeability (zonulin), immune reactivity to gliadin
Detox and recirculation signals — beta-glucuronidase, and on more comprehensive panels, bile acids and short-chain fatty acids
In short: a stool test maps the terrain. And that terrain doesn't just show up as digestive complaints — brain fog, skin flares, joint symptoms, and immune reactivity frequently trace back to it too.
What it can't tell you
It does not diagnose SIBO. Stool reflects the colon, not the small intestine — more on this below.
It does not diagnose disease. It's not a substitute for endoscopy, colonoscopy, biopsy, or a physician workup.
DNA-based results aren't a measure of activity. A detected gene means a strain carries it — not that a toxin is actually being produced.
It's a single snapshot. Diet, medications, and supplements at the time of collection all shift the picture.
It doesn't tell you why. It shows you what. The driver underneath — motility, hormones, thyroid, stress — is the clinical work.
Knowing these limits is what keeps a protocol inside scope, and what stops a practitioner from over-treating a finding the test was never designed to establish.
Who Should Actually Run a Stool Test
Not every client needs a comprehensive stool panel, and testing to "look thorough" instead of to answer a specific question wastes the client's money and adds noise instead of clarity. Stool testing earns its place when one or more of the following is true:
There's a symptom picture to confirm — bloating, irregularity, reflux, loose stools, food sensitivities
A prior diagnosis needs a clearer picture — IBS, IBD, Candida, parasites, or another GI disorder that hasn't fully resolved
A systemic presentation has a suspected gut origin — this list is broader than most people expect: brain fog, fatigue, headaches, mood changes, joint pain, skin issues like eczema, seasonal allergies, recurrent infections, blood sugar and weight patterns, sleep disturbance, hormonal imbalance, and autoimmune symptoms
Nutrient deficiencies persist despite adequate intake — the question becomes whether digestion itself is the bottleneck
Food sensitivities or allergies are present — assessing gut lining status and whether food is actually being digested
The client is "stuck" — foundations are dialed in, symptoms persist or keep returning, and it's time for data instead of another round of trial and error
The reason the systemic list matters as much as the digestive one: the gut interfaces constantly with the immune system, the skin, and the nervous system — through barrier integrity, microbial metabolites, and immune signaling. A client's presenting complaint might be their skin or their head, not their stomach, and a stool panel can still be exactly the right test.
GI-MAP vs. Gut Zoomer vs. GI Effects: How the Major Stool Panels Compare
There isn't a single "best" comprehensive stool test — there are three commonly used platforms, each built differently.
The single clearest differentiator: GI Effects is the only one of the three that runs actual culture with organism-specific sensitivity testing — meaning it can tell a practitioner which antimicrobial a given organism actually responds to, rather than just detecting DNA presence. Gut Zoomer's strength is in permeability and autoimmune-adjacent markers, plus diversity and metabolite data built into the core panel. GI-MAP's strength is depth on H. pylori virulence factors and classic dysbiosis patterns.
One practical note: reference ranges aren't interchangeable across platforms. Secretory IgA, for example, has a different reference range on GI Effects than on GI-MAP — so a number that looks alarming on one report might be entirely normal on another. Switching platforms between a client's baseline and retest can look like a dramatic change when it's really just a different ruler.
Why SIBO Needs a Breath Test, Not a Stool Test
This is the single most common testing mistake in this space — on any stool panel.
The small intestine, where SIBO (small intestinal bacterial overgrowth) occurs, has relatively low bacterial density in a healthy person and is kept clear between meals by the migrating motor complex. The colon, by contrast, is supposed to be densely colonized — that's where fermentation, short-chain fatty acid production, and stool formation happen. A stool sample is the output of the colon.
Asking a stool panel to diagnose SIBO is a category error, not a sensitivity problem. No matter how comprehensive the panel, a stool sample simply doesn't characterize what's happening in the small intestine.
Breath testing — measuring hydrogen, methane, and hydrogen sulfide after a lactulose or glucose substrate — is the test that actually establishes whether SIBO is present, and which gas pattern dominates. Hydrogen tends toward diarrhea-predominant presentations. Methane is strongly associated with constipation, and this pattern is sometimes labeled IMO (intestinal methanogen overgrowth) rather than classic SIBO, since the organisms responsible are archaea, not bacteria. Hydrogen sulfide, measured on newer breath tests, tends toward diarrhea as well and has a distinct, sometimes described as "rotten egg," odor signature.
Stool testing still matters here — just for a different question. It reads the terrain that let overgrowth happen in the first place: digestive capacity (pancreatic elastase, steatocrit), motility signals (methanogens, constipation-associated organisms), opportunistic load, and mucosal immune status (secretory IgA). That's what tells a practitioner why the SIBO keeps coming back, not just that it's there.
The rule of thumb: if a client asks to "check for SIBO," a stool panel alone is the wrong answer — however comprehensive it looks. The two tests genuinely answer different questions, and used together — confirm the overgrowth on breath, read the terrain on stool, sequence the protocol around both — they're more useful than either is alone.
How to Actually Read the Report
Before getting into individual markers, there's a system worth understanding: units and reference ranges, the categories on the report, and — most importantly — the order to read them in.
Results are typically reported in colony-forming units (CFU) per gram of stool, in scientific notation (2.5e6 = 2,500,000 CFU/gram). "High" and "low" are relative to a reference population, not a disease threshold — in range doesn't mean optimal, and out of range doesn't automatically mean treat. Reference ranges themselves are built from known diseased samples rather than arbitrary cutoffs, and pathogen thresholds are typically correlated against an FDA-cleared assay — the exponent is doing the real work here: a value flagged high at 1.5x the reference range and one flagged at 100x the range are entirely different clinical conversations, even though both show up in red.
Read the report in this order:
Safety first — anything that means refer (positive occult blood, significantly elevated calprotectin, frank pathogens in a symptomatic client)
Digestion and absorption — elastase, steatocrit
Motility and transit signals — methanogens, constipation history
Inflammation, immune status, and barrier integrity — calprotectin, secretory IgA, zonulin
The microbial picture — commensals before opportunistic organisms (what's missing usually explains more than what's overgrown)
Metabolites, last — these confirm the story; they don't start it
Most practitioners start with the microbes. That's exactly why protocols get built in the wrong order — which brings up the part of this that actually determines whether a protocol works.
Six Common Misreads
A handful of interpretation habits show up over and over, and every one of them produces confident action on a misread — which is more dangerous than uncertainty, because it moves a practitioner forward with the wrong plan instead of pausing to get the right one.
Treating every flag. A flagged value is information, not an instruction.
Forgetting the context. Medications, diet, and collection timing all shift results — a panel run mid-antimicrobial course tells you about the intervention, not the baseline.
Giving a probiotic for whatever's low. A supplement doesn't address why a commensal species is depleted in the first place.
Ignoring what's low and only treating what's high. Depleted keystone species and low diversity often explain more clinically than an elevated opportunistic organism does.
Skipping foundational work before killing protocols. Bile, absorption, and motility need to be functioning before an antimicrobial protocol starts — not after.
Calling SIBO from a stool result. Terrain markers suggest why overgrowth is possible. They don't establish that it's present.
The Microbiome Itself: Commensals, Opportunistic Bacteria, and Diversity Ratios
Before getting to inflammation and barrier markers, it's worth spending real time on the microbial section of the report — this is usually the most crowded part of the panel, and the part most likely to get misread first instead of last.
Commensal and keystone flora
Trillions of microorganisms inhabit the human intestine, forming a complex ecosystem that plays a direct role in health. Commensal bacteria extract nutrients and energy from food, maintain gut barrier function, produce vitamins (including biotin and vitamin K), interact continuously with the immune system, and protect against colonization by potential pathogens. The goal here is diversity and balance, not maximum counts — disrupted commensal bacteria is what dysbiosis actually is, and it's associated with obesity, malnutrition, inflammatory bowel and autoimmune disease, neurological disorders, and cancer.
The read that matters most: when commensals are depleted, opportunistic organisms don't need to be aggressive to take hold — they just need the space. That's why the reading order above puts commensals before opportunistic organisms, not after.
Opportunistic and overgrowth bacteria
Most people carry these organisms without symptoms — they're normal background flora for most sources, and only become a problem at high levels or in immunocompromised clients. What drives overgrowth: depleted commensals, poor diet, low stomach acid or PPI use, reduced digestive capacity, constipation, antibiotic exposure, infection, and a weakened immune system. What it produces clinically: gastroenteritis-type symptoms, inflammation, bloating, gas, cramping, loose stools or constipation, food reactivity, and systemic symptoms like fatigue, brain fog, and skin changes.
One clinically important thread: certain opportunistic bacteria may help initiate the autoimmune process. If autoimmune-associated organisms are elevated on a report, that's a genuine referral trigger — an ANA at minimum, or a full panel (hsCRP, ANA, RF, ESR) if the broader picture warrants it.
Diversity indices: Shannon and Simpson
On platforms that report it, diversity is scored two ways. Shannon's Index measures richness — how many different species are present. Simpson's Index measures evenness — whether the ecosystem is genuinely balanced or dominated by a few species. Low diversity on either index is meaningful even when no single organism is flagged high; it's often the earliest, most honest signal of a gut under chronic stress from diet, antibiotics, or illness. The right response is addressing the drivers — fiber diversity, reduced antibiotic exposure, resolving an active infection — and letting diversity recover as a downstream result, not chasing the number directly.
The Firmicutes/Bacteroidetes (F/B) ratio
Firmicutes and Bacteroidetes are the two dominant phyla across the entire GI tract — Firmicutes are gram-positive, Bacteroidetes are gram-negative. A high F/B ratio specifically is linked to increased caloric extraction from food, fat deposition, impaired insulin sensitivity, and increased inflammation. Common drivers include poor diet, dysbiosis, and maldigestion or hypochlorhydria. When Firmicutes is high, favoring Bifidobacterium and Saccharomyces boulardii tends to help more than reaching for Lactobacillus- or Bacillus-containing probiotics, which can actually push Firmicutes higher. A lower-fat diet may also help normalize the ratio — but as with diversity, the ratio itself is a downstream signal, not the target.
The Prevotella/Bacteroides (P/B) ratio
Prevotella and Bacteroides are the two dominant genera within Bacteroidetes — both gram-negative, unlike the gram-positive/gram-negative split in the F/B ratio. Diet is the main driver: plant-rich, high-fiber diets favor Prevotella, while protein- and fat-rich Western diets favor Bacteroides. A low P/B ratio is associated with a Western dietary pattern, higher BMI, and increased metabolic syndrome risk. A high P/B ratio is genuinely context-dependent — it can reflect a favorable, fiber-rich diet profile and even predict a better fat-loss response, but the same genus shows up more dominant in some obesity and IBS-diarrhea presentations too. The practical rule: read a high P/B result against the client's actual symptom picture rather than assuming it's automatically good or bad.
Fungi, parasites, and pathogens
Fungal and yeast overgrowth (Candida species being the most familiar) frequently coexists with bacterial dysbiosis rather than replacing it, and is driven by antibiotic exposure, high sugar intake, low stomach acid, and impaired immune function — with presentations ranging from bloating and sugar cravings to recurrent yeast infections and certain skin issues. Parasites and worms are flagged through travel, food, water, and pet-exposure history as much as through the lab result itself, since intermittent shedding means a single negative sample doesn't fully rule one out. True pathogens (the organisms that commonly cause gastroenteritis) deserve a different level of caution than the rest of the microbial section: not every positive finding produces symptoms, a positive toxin gene is not the same as a measured toxin level on a DNA-based panel, and significant findings in a symptomatic client are a referral, not a protocol.
Marker by Marker: What the Report Is Actually Telling You
This is the section most interpretation guides skip, and it's where the real skill lives. A handful of markers show up across nearly every comprehensive panel, and each one is worth understanding on its own terms rather than as just another red or green flag.
Calprotectin
Fecal calprotectin is the most studied marker of gastrointestinal inflammation, and it's the primary tool used to differentiate inflammatory bowel disease from irritable bowel syndrome. Mild elevation is often seen with dysbiosis or food sensitivity and is reasonable to address and retest in 60–90 days. NSAIDs and recent infection can both elevate it transiently, which is worth ruling out before drawing conclusions. Persistent or significant elevation — particularly anything suggesting IBD, polyps, diverticulitis, or colorectal cancer — is a safety marker before it's anything else, and warrants medical referral rather than a botanical protocol.
MMP-9 (Matrix Metalloprotease-9)
MMP-9 is a repair enzyme, upregulated specifically by active GI tissue damage — a sign of tissue matrix breakdown, not just generic inflammation. It's significantly elevated in ulcerative colitis compared with both healthy controls and IBS, which makes it one of the more useful markers for distinguishing an inflammatory bowel disease picture from a functional one. It also correlates with clinical and endoscopic disease activity, and it's used as a non-invasive way to track mucosal healing over time. Read it the same way as calprotectin: a significant elevation raises the case for referral and formal workup, not a supplement decision.
Secretory IgA (sIgA)
Secretory IgA is the gut's first line of immune defense, produced by mucosal tissue to bind toxins and pathogens before they reach the epithelium. A high result tends to reflect a more acute picture — active dysbiosis, infection, or antigen exposure. A low result tends to reflect something more chronic — a suppressed gut immune system, often from longstanding dysbiosis, chronic stress, or protein malnutrition. Low sIgA specifically matters for interpreting other markers too: it can blunt an anti-gliadin result, producing a false negative in a client who's genuinely reactive to gluten.
Intestinal Permeability (Zonulin)
Zonulin regulates the tight junctions between the epithelial cells lining the gut — essentially the gatekeeper protein that opens for nutrient absorption but can become chronically overstimulated. Elevated zonulin is the biomarker most directly associated with "leaky gut," and it's implicated in autoimmune disease, metabolic disorders, and chronic inflammatory conditions. Key triggers include dysbiosis (especially gram-negative, LPS-producing bacteria), gluten exposure, chronic stress, and NSAID or alcohol use. Fecal zonulin is considered more specific to gut permeability than serum zonulin, which can originate from the liver, fat tissue, brain, or skin and is a less specific systemic signal.
Anti-Gliadin IgA
Gliadin is the protein fraction of gluten found in wheat, rye, barley, kamut, and spelt. Anti-gliadin antibodies indicate an immune response to gliadin — but the result only means something under specific conditions. Gluten has to actually be in the diet at the time of collection for the antibody to register, so a strictly gluten-free client can test negative regardless of underlying sensitivity. As noted above, low sIgA can also blunt the result. This marker is not a substitute for a celiac diagnosis; tTg2 and deamidated gliadin peptide (DGP), where available, sharpen that referral conversation considerably.
Beta-Glucuronidase
This is a Phase II detoxification enzyme with a specific and somewhat counterintuitive mechanism. The liver normally attaches glucuronic acid to a hormone or toxin and excretes that complex into bile for elimination through the intestine. Beta-glucuronidase can break that bond back apart, allowing what the liver just packaged for removal to be reabsorbed and recirculated instead — and it can convert certain pro-carcinogens into active carcinogenic compounds. Persistently high levels suggest unhealthy colonic changes, with increased risk tied to hormone-sensitive and digestive tract cancers, and are stimulated by dysbiosis, toxin burden, high dietary protein (particularly red meat), and antibiotic use.
H. Pylori and Virulence Factors
H. pylori colonizes the gastric mucosa and directly alters stomach acid production, commonly transmitting via oral-to-oral contact, fecal contamination, or within families. A positive result near the reference cutoff in an asymptomatic client with no other dysbiosis is often a watchful case; a positive result in a symptomatic client, or one driving downstream overgrowth, warrants treatment. Virulence factor genes — CagA and VacA in particular — increase disease potential and are associated with peptic ulcer disease and gastric cancer; a positive result for either in a symptomatic client should lower the threshold to involve a physician. One safety point worth repeating on its own: betaine HCl should not be started during the early phase of H. pylori treatment, or with active gastric ulceration, since adding acid to an already-inflamed gastric lining can worsen irritation and reflux.
The Gut-Brain, Gut-Skin Connection: How LPS and Endotoxemia Actually Work
This is the mechanism that explains why a gut finding can show up as fatigue, brain fog, or a skin flare instead of a digestive complaint — and it's worth understanding on its own, separate from any single marker.
Many of the organisms found on a comprehensive stool panel are gram-negative, meaning their outer membrane contains lipopolysaccharide (LPS) — an endotoxin. With an intact gut barrier, LPS stays contained in the gut lumen. With a permeable barrier — the same permeability a zonulin test is measuring — LPS can leak into general circulation. That's endotoxemia.
Once in circulation, LPS triggers a systemic inflammatory response. This is the actual mechanistic thread connecting a gut finding to symptoms that look completely unrelated to digestion: fatigue, brain fog, and skin symptoms among them. It's also worth knowing that this isn't a coincidence limited to a few unlucky organisms — most of the autoimmune-associated and opportunistic bacteria that show up on a stool report are gram-negative, which is exactly why permeability status changes how seriously a practitioner should take an elevated finding.
On platforms that test for it, the LPS antibody marker is measuring something specific and easy to misunderstand: it is not testing for LPS itself. It's testing immune reactivity to LPS that has already crossed a permeable barrier. An elevated LPS antibody is evidence that the leak has been happening long enough for the immune system to mount a measurable response to it — which is a more clinically useful piece of information than "permeability is present," because it speaks to duration and immune engagement, not just a single snapshot.
From Markers to Protocol: Why Sequencing Is Everything
Here's the idea that changes the most in how a practitioner works once it clicks: a set of results is not a protocol. Symptoms, history, and labs together tell the story — designing the protocol from that story is the clinical skill, not a lookup exercise where a flagged marker maps directly to a supplement.
The most common failure mode is chasing every flagged value at once — every red flag gets a product, eight to twelve supplements go out in the same week, the client flares, and nobody can tell which variable did what.
Why the order matters more than the products:
Clear before digestion is actually working, not just "open" — stomach acid and enzymes are the first line of defense against overgrowth. Clear without that defense functioning and the thing that let the overgrowth happen in the first place is still broken.
Clear before motility and detox pathways are open — die-off produces a real toxic load. Without an exit route (bowel motility, liver conjugation, bile), that load recirculates instead of leaving — and a normal herx reaction gets misread as the protocol failing.
Clear before bile is supported — bile is also directly antimicrobial in the small intestine, so losing that function at exactly the wrong moment works against the clearing itself.
Stop at clearing, skip repair and rebuild — the lining that let this happen never gets rebuilt, and the commensal base never gets restored. Recurrence isn't bad luck; it's built into the sequence.
The takeaway that tends to land hardest with practitioners: the products rarely fail. The order does. A client who's been through multiple rounds of antimicrobial treatment, with real but temporary relief each time, usually isn't dealing with a resistant infection — they're dealing with a protocol that keeps skipping the sequence that would make the result hold.
What a fully sequenced approach actually looks like
Zooming out past any single marker, a well-sequenced root-cause protocol tends to move through a consistent arc regardless of which organisms or markers are involved:
Testing — stool plus, where indicated, a SIBO breath test. You can't treat what you haven't measured, and testing replaces guessing with sequencing rather than adding another guess on top of the last one.
Remove — identify and reduce what's actively driving dysfunction: food triggers, environmental toxin exposure, and lifestyle stressors, while building basic foundations (blood sugar regulation, hydration, sleep) that make everything downstream more effective.
Eradicate + Restore — address confirmed overgrowth (SIBO, Candida, parasites, H. pylori) with herbal or pharmaceutical antimicrobials matched to the organism and the client's capacity to tolerate treatment, restore the mucosal lining, and support digestion as needed. This phase is the most metabolically demanding of the whole sequence, and extra mitochondrial support here isn't optional — it's what keeps a client functional while the heavier lifting is happening.
Repair, Rebalance, and Reintroduction — this is where most clients get abandoned on an overly restrictive diet indefinitely. The real work here is a structured reintroduction of previously eliminated foods, continued mucosal repair as the diet expands, and rebuilding the microbiome with strain-specific probiotics, prebiotics, and tolerated fermented foods.
Detox and Cellular Health — phased, not rushed: drainage pathways (bowels, bile flow, lymph, kidneys, sweat) open first, then liver and Phase II support, and only then — if indicated — more targeted work like mycotoxin binders or metal chelation, ideally under clinical oversight.
Retest and Advance — confirm progress by rerunning the panels that actually drove the protocol, rather than guessing at outcomes, before advancing to the next phase or layering in additional goals like performance or longevity work.
The common thread through every phase: testing is step one, not the whole plan. Every phase is sequenced around the person in front of you, not the markers on the page.
The Bottom Line
Reading a stool test well means treating it as one data point inside a much bigger picture — history, symptom timeline, stress, hormones, thyroid, training load, life — rather than the whole story. A number on a page means very little until it's read against the person it belongs to.
That shift — from running tests to actually using them — is the difference between a coach who orders panels and a practitioner who reads them.
FAQ
Can a stool test diagnose SIBO? No. SIBO is a small intestinal finding, and a stool sample reflects colon output. A breath test (measuring hydrogen, methane, and hydrogen sulfide) is required to diagnose SIBO; stool testing is still useful for understanding what let the overgrowth happen.
What's the difference between GI-MAP and Gut Zoomer? GI-MAP is a qPCR-only panel with strong H. pylori virulence factor reporting. Gut Zoomer combines qPCR with mass spectrometry and chemiluminescence, and includes permeability markers (zonulin), gut antibodies (LPS, ASCA, tTg2, DGP), and diversity indices built into its core panel.
What does elevated zonulin actually mean? Zonulin regulates the tight junctions between gut lining cells. An elevated result indicates increased intestinal permeability — sometimes called "leaky gut" — and is implicated in autoimmune, metabolic, and chronic inflammatory conditions. Fecal zonulin is considered more specific to gut permeability than a serum zonulin result.
Can gut bacteria really cause fatigue or brain fog? Indirectly, yes, through a well-described mechanism. Many gut organisms are gram-negative and carry an endotoxin called LPS on their outer membrane. If the gut barrier is permeable, LPS can enter circulation and trigger a systemic inflammatory response — which is one documented pathway connecting gut findings to fatigue, brain fog, and skin symptoms that have nothing to do with digestion on the surface.
How long does it take to resolve a bacterial or fungal overgrowth? Mild presentations typically run 4–12 weeks; moderate to severe or multi-organism presentations can run 12–20 weeks. Duration — not dose escalation — is usually the lever that changes between a moderate and a severe case.
Do I need to treat every organism flagged on a stool test? No. A flagged value is information, not an instruction. Many findings reflect asymptomatic carriage, and over-treating a mild or isolated finding can create more disruption than it resolves.
Is a positive finding on a stool test always something to treat? Not automatically. Context matters — the client's symptom picture, other markers on the same panel, and their history all factor into whether a finding is a treat-it-now signal or a watch-and-recheck one.
What's the difference between fecal and serum zonulin testing? Fecal zonulin is considered a more specific marker of gut permeability. Serum zonulin can originate from other tissues — the liver, fat tissue, brain, or skin — making it a less specific, more systemic signal.
What is the Firmicutes/Bacteroidetes (F/B) ratio, and why does it matter? Firmicutes and Bacteroidetes are the two dominant bacterial phyla in the gut. A high F/B ratio is linked to increased caloric extraction, fat deposition, impaired insulin sensitivity, and inflammation, and is typically driven by diet, dysbiosis, or maldigestion rather than being a standalone problem to chase directly.
Is a high Prevotella/Bacteroides (P/B) ratio good or bad? It depends on the client's full picture. A high P/B ratio can reflect a favorable, fiber-rich diet and predict a better fat-loss response — but the same genus is also more dominant in some obesity and IBS-diarrhea presentations. The ratio has to be read against symptoms and history, not treated as automatically positive or negative.
Watch the full training:
Ready to Go Deeper? Meet the RSN Institute of Functional Nutrition
Everything in this guide is one skill: reading a comprehensive stool panel and sequencing a protocol around it. The RSN Institute of Functional Nutrition is where that skill becomes a full clinical system — a certification built for coaches and practitioners who want to work root-cause, with the credentials and confidence to back it up.
What the program actually covers
Tier 1 lays the functional nutrition foundation across eight core areas: the functional nutrition framework itself, body composition, adrenals and chronic stress, thyroid, female hormones, gut microbiome and gut health, and detoxification.
Tier 2 goes deeper into the clinical and lab-interpretation skills this guide only had room to introduce — stool testing and protocols across platforms (including GI Effects), SIBO breath testing and advanced gut protocols, DUTCH hormone testing, thyroid testing and protocols, genetic testing, lipids and inflammation, aesthetic labs, and mastering cortisol, among others.
Tier 2 also includes a weekly live Q&A call with real case studies, a weekly live lab-testing interpretation session, a private practitioner community, and downloadable protocols, meal plans, and resources — so the learning doesn't stop at the course material.
Board certification that actually means something
Graduates aren't just finishing a course — they're pre-qualified for board certification through the American Natural Wellness Practitioners Board (ANWPB) exam, with recognition from the American Association of Nutrition Practitioners (AANWP) and the American Association of Nutrition Consultants (AANWC), and eligibility for a Board Certified Nutrition Professional (BCNP) or Board Certified Doctor of Clinical Nutrition (BCDCN) credential — plus legal eligibility to practice as a holistic nutrition professional in all 50 states. RSN is also an approved AANWP continuing education provider, so ongoing coursework counts toward maintaining the credential rather than existing separately from it.
What happens on the call
Enrollment starts with a short admission call — think of it as a fit conversation, not a sales pitch. It's a chance to walk through where a practitioner's business is right now, what they're trying to build, and whether this program's structure and pacing actually make sense for that goal before anyone commits to anything.
Book your free admission call/interview here →